- Home
- FTDR vs FOLD Comparison
FTDR vs FOLD Comparison
Compare FTDR & FOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FTDR | FOLD |
|---|---|---|
| Founded | 1971 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.5B |
| IPO Year | 2019 | 2006 |
Fundamental Metrics
Financial Performance| Metric | FTDR | FOLD |
|---|---|---|
| Price | $61.46 | $14.49 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $67.20 | $27.25 |
| AVG Volume (30 Days) | 548.2K | ★ 2.3M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 13.62 | ★ 50.00 |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $2,093,000,000.00 | N/A |
| Revenue This Year | $5.97 | $20.50 |
| Revenue Next Year | $5.82 | $18.59 |
| P/E Ratio | $109.69 | ★ N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $48.47 | $5.66 |
| 52 Week High | $70.77 | $14.50 |
Technical Indicators
Market Signals| Indicator | FTDR | FOLD |
|---|---|---|
| Relative Strength Index (RSI) | 46.57 | 74.18 |
| Support Level | $55.98 | $14.21 |
| Resistance Level | $62.88 | N/A |
| Average True Range (ATR) | 3.31 | 0.02 |
| MACD | -0.52 | -0.00 |
| Stochastic Oscillator | 27.72 | 100.00 |
Price Performance
Historical ComparisonAbout FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About FOLD Amicus Therapeutics Inc.
Amicus Therapeutics Inc is a biotechnology company focused to develop and deliver transformative medicines for people living with rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.